Bio-Techne stock is trading -21.35% below its average target price of $86.96 after dropping -6.1% during today's morning session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $75.0 to $95.0 per share.
The stock has an average amount of shares sold short at 2.9%, and a short ratio of 5.32. The company's insiders own 1.04% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.5% of Bio-Techne's shares being owned by this investor type.
Institutions Invested in Bio-Techne
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Vanguard Group Inc | 12% | 18,318,964 | $1,252,833,936 |
| 2024-12-31 | Blackrock Inc. | 9% | 14,036,494 | $959,955,816 |
| 2024-09-30 | Price (T.Rowe) Associates Inc | 6% | 9,424,313 | $644,528,760 |
| 2024-09-30 | State Street Corporation | 4% | 6,395,993 | $437,421,957 |
| 2024-09-30 | Morgan Stanley | 3% | 4,657,591 | $318,532,645 |
| 2024-09-30 | BAMCO Inc. | 3% | 4,445,540 | $304,030,477 |
| 2024-09-30 | Ameriprise Financial, Inc. | 3% | 4,385,593 | $299,930,702 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 3,902,636 | $266,901,273 |
| 2024-09-30 | Neuberger Berman Group, LLC | 2% | 3,516,092 | $240,465,529 |
| 2024-09-30 | Invesco Ltd. | 2% | 3,461,708 | $236,746,208 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Bio-Techne.
